Pharmexa obtains approval in Russia
Patients in the phase II trial with HER-2 Protein AutoVac(TM) in combination with the adjuvant QS-21 will receive four initial immunisations over a six week period with 1.25 milligram HER-2 Protein AutoVac formulated with Alhydrogel adjuvant and mixed with QS-21 adjuvant, followed by booster immunisations every four weeks for up to 26 weeks. The trial will be carried out at 10-15 cancer research centres in Poland, Romania and Russia. According to plan the centres will recruit 40 patients with active HER-2 positive breast cancer.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.